Literature DB >> 33104270

At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Gary D Luker1, Jinming Yang2, Ann Richmond2, Stefania Scala3, Claudio Festuccia4, Margret Schottelius5, Hans-Jürgen Wester6, Johann Zimmermann7.   

Abstract

Signaling through chemokine receptor, C-X-C chemokine receptor type 4 (CXCR4) regulates essential processes in normal physiology, including embryogenesis, tissue repair, angiogenesis, and trafficking of immune cells. Tumors co-opt many of these fundamental processes to directly stimulate proliferation, invasion, and metastasis of cancer cells. CXCR4 signaling contributes to critical functions of stromal cells in cancer, including angiogenesis and multiple cell types in the tumor immune environment. Studies in animal models of several different types of cancers consistently demonstrate essential functions of CXCR4 in tumor initiation, local invasion, and metastasis to lymph nodes and distant organs. Data from animal models support clinical observations showing that integrated effects of CXCR4 on cancer and stromal cells correlate with metastasis and overall poor prognosis in >20 different human malignancies. Small molecules, Abs, and peptidic agents have shown anticancer efficacy in animal models, sparking ongoing efforts at clinical translation for cancer therapy. Investigators also are developing companion CXCR4-targeted imaging agents with potential to stratify patients for CXCR4-targeted therapy and monitor treatment efficacy. Here, pre-clinical studies demonstrating functions of CXCR4 in cancer are reviewed. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  CXCL12; CXCR4 antagonist; CXCR4 inhibitor; chemokine; radioimaging; tumor

Mesh:

Substances:

Year:  2020        PMID: 33104270      PMCID: PMC8254203          DOI: 10.1002/JLB.2BT1018-715RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  308 in total

1.  Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor.

Authors:  Gregory J Babcock; Michael Farzan; Joseph Sodroski
Journal:  J Biol Chem       Date:  2002-11-13       Impact factor: 5.157

2.  CXCR4-CCR5: a couple modulating T cell functions.

Authors:  Rita Lucia Contento; Barbara Molon; Cedric Boularan; Tullio Pozzan; Santos Manes; Stefano Marullo; Antonella Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-15       Impact factor: 11.205

3.  Improvement of CXCR4 tracer specificity for PET imaging.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence P Szajek; Gang Niu; Ying Ma; Dale O Kiesewetter; Amnon Peled; Henry S Eden; Joshua M Farber; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-09-22       Impact factor: 9.776

4.  Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.

Authors:  Sheng-Bin Peng; Xiaoyi Zhang; Donald Paul; Lisa M Kays; Wendy Gough; Julie Stewart; Mark T Uhlik; Qi Chen; Yu-Hua Hui; Maciej J Zamek-Gliszczynski; John A Wijsman; Kelly M Credille; Liang Zeng Yan
Journal:  Mol Cancer Ther       Date:  2014-12-12       Impact factor: 6.261

5.  64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors:  Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal:  Bioorg Med Chem       Date:  2009-01-15       Impact factor: 3.641

6.  Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.

Authors:  Veronique Bodart; Virginia Anastassov; Marilyn C Darkes; Stefan R Idzan; Jean Labrecque; Gloria Lau; Renee M Mosi; Kathleen S Neff; Kim L Nelson; Melanie C Ruzek; Ketan Patel; Zefferino Santucci; Robert Scarborough; Rebecca S Y Wong; Gary J Bridger; Ron T Macfarland; Simon P Fricker
Journal:  Biochem Pharmacol       Date:  2009-06-18       Impact factor: 5.858

7.  Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.

Authors:  Jinming Yang; Amrendra Kumar; Anna E Vilgelm; Sheau-Chiann Chen; Gregory D Ayers; Sergey V Novitskiy; Sebastian Joyce; Ann Richmond
Journal:  Cancer Immunol Res       Date:  2018-08-14       Impact factor: 11.151

Review 8.  Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier.

Authors:  Tyler Etheridge; Shivashankar Damodaran; Adam Schultz; Kyle A Richards; Joseph Gawdzik; Bing Yang; Vincent Cryns; David F Jarrard
Journal:  Asian J Urol       Date:  2018-09-15

9.  A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer1,2.

Authors:  Shuang Zhao; S Laura Chang; Jennifer J Linderman; Felix Y Feng; Gary D Luker
Journal:  Transl Oncol       Date:  2014-05-13       Impact factor: 4.243

Review 10.  Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD.

Authors:  Irma Tindemans; Maria E Joosse; Janneke N Samsom
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

View more
  4 in total

1.  The CXCL12/CXCR4/ACKR3 Signaling Axis Regulates PKM2 and Glycolysis.

Authors:  Kathryn E Luker; Gary D Luker
Journal:  Cells       Date:  2022-05-28       Impact factor: 7.666

Review 2.  CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment.

Authors:  Sara Santagata; Caterina Ieranò; Anna Maria Trotta; Anna Capiluongo; Federica Auletta; Giuseppe Guardascione; Stefania Scala
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

3.  Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists.

Authors:  Mastaneh Safarnejad Shad; Sandra Claes; Eline Goffin; Tom Van Loy; Dominique Schols; Steven De Jonghe; Wim Dehaen
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

4.  A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model.

Authors:  Elisa Rioja-Blanco; Alberto Gallardo; Irene Arroyo-Solera; Patricia Álamo; Isolda Casanova; Ugutz Unzueta; Naroa Serna; Laura Sánchez-García; Miquel Quer; Antonio Villaverde; Esther Vázquez; Xavier León; Lorena Alba-Castellón; Ramon Mangues
Journal:  Pharmaceutics       Date:  2022-04-18       Impact factor: 6.525

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.